Novartis drug everolimus has been reviewed in the UK as a second-line drug for the treatment of renal cell carcinoma

Source: biovale 2017-01-17 the National Institute of health and care of the UK abolished the previous regulation on Everest and recommended the drug as a conventional drug for the treatment of renal tumors Since the UK launched the nice 2011 program to re evaluate all cancer drug fund supported treatment programs, Everest can only be used after passing the program review Now that Novartis has provided new evidence, nice has approved the drug as a second-line treatment for advanced renal cell carcinoma (RCC) Professor Carole longson, director of nice Health Technology Evaluation Center, said: "renal cell carcinoma is a relatively rare cancer, so there is limited choice of treatment drugs Novartis actively cooperated in the drug review process, providing a large number of data to show that their drug is effective and has a certain price performance, so we recommend the use of the drug " Everolimus is a once-a-day oral drug, which is suitable for patients who are still in progress after 6 months of targeted treatment with vascular endothelial growth factor (VEGF) The clinical trial data re submitted by Novartis showed that the progression free survival time of patients after VEGF targeted therapy was extended by nearly 3 months, and the total survival time was at least 3 months longer than that of the control group After the final approval, Novartis' drug will compete with Bristol Myers Squibb's second-line RCC treatment drug, navumab, which is also being reevaluated by nice However, in a recent phase 3 clinical trial, nafumab extended the mean overall survival time by 5.4 months and produced fewer side effects compared with the administration of everolimus